Vyera Pharmaceuticals
Data Collection & Internet Portals · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
600 3rd Ave Fl 10, New York City, New Yo...Phone Number
(212) 202-5935Website
www.vyera.comRevenue
$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Vyera Pharmaceuticals
Vyera Pharmaceuticals is a biopharmaceutical company that develops and commercializes medicinal treatments. Vyera was founded in 2015 and is headquartered in New York.Explore more
Vyera Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vyera Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Vyera Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Vyera Pharmaceuticals launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Vyera Pharmaceuticals recently announced quarterly report
Vyera Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Vyera Pharmaceuticals is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Vyera Pharmaceuticals
Website visits: Recent activity has been detected on your website
Click to see if Vyera Pharmaceuticals had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Vyera Pharmaceuticals has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Vyera Pharmaceuticals
Compare insights from companies similar to Vyera Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Vyera Pharmaceuticals
$5M
51-200
Private
$90M
2015
NP
Nicholas PelliccioneSenior VP Head of Research & Development
Company Profile Activity
Activity Insights
Vyera Pharmaceuticals is experiencing very low activity levels compared to other companies in the Media & Internet sector.
What does this means?
Vyera Pharmaceuticals is drawing exceptional interest within the Media & Internet industry, suggesting notable developments or strong market momentum, learn more about Vyera Pharmaceuticals.
Vyera Pharmaceuticals financials insights
Gather financial insights about Vyera Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$90M
Vyera Pharmaceuticals Tech Stack
A closer look at the technologies used by Vyera Pharmaceuticals
Most Recent Scoops
Pain Point
Pain Point, Bankruptcy
Pain Point
Pain Point, Spending/Investment, Compliance, Lawsuits, Legal Affairs
Left Company
Executive Move
Nancy Retzlaff, Chief Commercial Officer, has left the organization.
Executive Moves, Personnel Moves, Left Company
Lateral Move
Left Company
Executive Move
Nicholas Pelliccione, Senior. VP, Head of Research & Development has assumed the responsibilities of Eliseo Salinas, who recently left the organization.
Executive Moves, Research & Development, Left Company
Project
Branding
Vyera Pharmaceuticals News & Media
Martin Shkreli-founded drug company files for bankruptcy - Yahoo News
Vyera Pharmaceuticals, which previously settled price-fixing charges that resulted in founder Martin Shkreli being banned from the pharmaceutical industry, filed for bankruptcy late Tuesday to sell its assets. Vyera said its bankruptcy was the result of declining profits, increased competition for generic drugs, and litigation alleging that Vyera suppressed competition for its most valuable drug, Daraprim. Daraprim is a life-saving anti-parasitic medicine that Shkreli infamously raised the priceMartin Shkreli-founded drug company files for bankruptcy - WTVB
By Dietrich Knauth NEW YORK (Reuters) - Vyera Pharmaceuticals, which previously settled price-fixing charges that resulted in founder Martin Shkreli b...Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase the Remaining Royalties Payable to Phoenixus AG for SLS-002 (Intranasal Racemic Ketamine Program), All Future Success and Commercial Based Milestones and the Change of Control Fee
NEW YORK, April 11, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today an amendment of the agreement with Phoenixus AG,...Federal Court Imposes Penalties on Former CEO and Large Shareholder of Pharmaceutical ...
On January 14, 2022, a federal court in New York issued its decision in Federal Trade Commission v. Shkreli, holding that Martin Shkreli, the former head of Vyera Pharmaceuticals, violated federal and state antitrust laws by allegedly interfering with the entry of generic competition for Vyera’s drug Daraprim.
Read more news
Top Data Collection & Internet Portals Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Vyera Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Vyera Pharmaceuticals is a biopharmaceutical company that develops and commercializes medicinal treatments. Vyera was founded in 2015 and is headquartered in New York.... Read More
